Andrew Bellinger - Dec 22, 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role: Chief Scientific Officer
Signature: /s/ Andrew Ashe, as Attorney-in-Fact for Andrew Bellinger
Stock symbol: VERV
Transactions as of: Dec 22, 2021
Transactions value $: -$558,269
Form type: 4
Date filed: 12/27/2021, 05:12 PM
Previous filing: Dec 17, 2021
Next filing: Feb 15, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VERV	Common Stock	Options Exercise	$22.2K	+15K	+300%	$1.48^*	20K	Dec 22, 2021	Direct
transaction	VERV	Common Stock	Sale	-$73.6K	-1.97K	-9.84%	$37.42	18K	Dec 22, 2021	Direct	F1, F2
transaction	VERV	Common Stock	Sale	-$315K	-8.16K	-45.26%	$38.60	9.87K	Dec 22, 2021	Direct	F1, F3
transaction	VERV	Common Stock	Sale	-$192K	-4.87K	-49.35%	$39.37	5K	Dec 22, 2021	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VERV	Stock Option (right to buy)	Options Exercise	$0	-15K	-9.26%	$0.00	147K	Dec 22, 2021	Common Stock	15K	$1.48	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2021.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.99 to $37.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) of this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.03 to $38.95, inclusive.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $39.98, inclusive.
F5	The remaining shares underlying this option, which was granted on September 17, 2019 and commenced vesting on October 1, 2019, vest in equal monthly installments until October 1, 2023.